The current guidelines developed by the Japanese Diabetes Society recommend that the type(s) of glucose‐lowering agents should be individualized for each patient according to the disease characteristics as well as the pharmacological and safety profiles of each drug.30 In the present study, we observed marked differences in the baseline characteristics of patients treated with SGLT2 inhibitors or DPP‐4 inhibitors in real‐world settings in Japan, suggesting that SGLT2 inhibitors are often used later in the treatment regimen. This evidence concerns the gene SLC5A2 and diabetes mellitus.